489 related articles for article (PubMed ID: 36567502)
1. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
Eliasson B; Ekelund J; Holmberg CN; Wolden ML; Matthiessen KS; James S
Eur J Prev Cardiol; 2023 May; 30(7):546-551. PubMed ID: 36567502
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
3. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
[TBL] [Abstract][Full Text] [Related]
4. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
5. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.
Davies MJ; Drexel H; Jornayvaz FR; Pataky Z; Seferović PM; Wanner C
Cardiovasc Diabetol; 2022 Aug; 21(1):144. PubMed ID: 35927730
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
McGuire DK; Busui RP; Deanfield J; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter N; Engelmann MDM; Hovingh GK; Ripa MS; Gislum M; Brown-Frandsen K; Buse JB
Diabetes Obes Metab; 2023 Jul; 25(7):1932-1941. PubMed ID: 36945734
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
[TBL] [Abstract][Full Text] [Related]
9. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
10. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
Mosenzon O; Alguwaihes A; Leon JLA; Bayram F; Darmon P; Davis TME; Dieuzeide G; Eriksen KT; Hong T; Kaltoft MS; Lengyel C; Rhee NA; Russo GT; Shirabe S; Urbancova K; Vencio S;
Cardiovasc Diabetol; 2021 Jul; 20(1):154. PubMed ID: 34315481
[TBL] [Abstract][Full Text] [Related]
11. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes and cardiovascular disease: risk reduction and early intervention.
Hinnen D; Kruger D; Magwire M
Postgrad Med; 2023 Jan; 135(1):2-12. PubMed ID: 36154802
[TBL] [Abstract][Full Text] [Related]
13. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
Østergaard HB; Humphreys V; Hengeveld EM; Honoré JB; Mach F; Visseren FLJ; Westerink J; Yadav G; Mosenzon O;
Diabetes Obes Metab; 2023 Feb; 25(2):435-443. PubMed ID: 36199242
[TBL] [Abstract][Full Text] [Related]
15. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
17. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
19. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
